Funding news · Sep 4, 2026
OsseoLabs Raises $50.1K Seed Round for AI-Driven Surgical Planning
OsseoLabs Closes Seed Round
OsseoLabs, a medical-technology company building patient-specific implants and AI-driven surgical planning, has raised $50,100 in a Seed round. The funding was recorded on September 4, 2026.
No lead investor was named in the transaction, and no investor list was disclosed.
What OsseoLabs Does
OsseoLabs operates at the intersection of 3D printing, AI and orthopedic surgery. Its core offerings include:
- OsseoVision — a web platform that uses AI to generate bone models, personalized implants and custom surgical guides.
- OsseoMatrix — a patented porous architecture that underpins the company's implant lines.
- Bioresorbable magnesium 3D-printing platform — a technology platform supporting implant development.
The company's implant lines span several clinical areas:
- Mandibular reconstruction
- Orthognathic surgery
- Cranioplasty
- Spine
- Extremities
Together, these cover orthopedic and cranio-maxillofacial surgery — procedures where patient-specific geometry and precise surgical planning are critical.
Company Background
OsseoLabs was founded in 2021 by Patcharapit Promoppatum, a 3D-printing researcher, and Vikram Ahuja, a serial founder.
The company is incorporated in Delaware and operates from the Indianapolis, Indiana area, with an additional presence in Bangkok. It is also a Johnson & Johnson JLABS portfolio company — a detail that signals engagement with one of the largest healthcare organizations in the world.
Deal Summary
| Detail | Value |
|---|---|
| Company | OsseoLabs |
| Round Type | Seed |
| Amount | $50,100 USD |
| Funding Date | September 4, 2026 |
| Lead Investor | Not disclosed |
| Investors | Not disclosed |
Why It Matters
Patient-specific implants and AI-driven surgical planning represent a convergence of several maturing technologies: medical imaging, computational modeling, additive manufacturing and, increasingly, AI-assisted design workflows.
OsseoLabs' approach combines a software layer (OsseoVision) with hardware and materials innovation (OsseoMatrix and the magnesium 3D-printing platform). That pairing — digital planning plus physical implant production — is the kind of vertically integrated model that can differentiate a medtech company in orthopedic and cranio-maxillofacial markets.
The breadth of the implant portfolio is also notable. Rather than focusing on a single procedure, OsseoLabs spans mandibular reconstruction, orthognathic surgery, cranioplasty, spine and extremities. Each of these areas demands high levels of customization, which aligns with the company's patient-specific design premise.
What to Watch
As a Seed-stage company, OsseoLabs will be judged on its ability to move its platform through clinical and regulatory pathways and to demonstrate adoption of OsseoVision and its implant lines. Its JLABS affiliation and dual presence in the Indianapolis area and Bangkok give it footholds in both U.S. and Southeast Asian medtech ecosystems.
For observers tracking early-stage medtech, OsseoLabs sits in a technically demanding niche where AI-driven planning and bioresorbable materials could reshape how orthopedic and cranio-maxillofacial implants are designed and delivered.